Vertex Pharmaceuticals Stock News

Over the past 3 months, 5 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ: VRTX ) stock. These analysts

BMO Capital Markets initiated coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report report published on Thursday, Price Targets.com reports. The firm issued a market perform rating and a $202.00 price target on the pharmaceutical companys stock. A number of other equities research analysts also recently weighed in on VRTX. SVB Leerink boosted []

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Spanish government has approved terms for the national reimbursement of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) for eligible patients. The agreement covers people with CF ages 12 years and older who have at least one copy of the F508del mutation, regardless of the other mutation type in the CFTR gene. KAFTRIO®

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shot up 4.2% on Wednesday . The company traded as high as $197.25 and last traded at $196.20. 24,720 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 1,946,572 shares. The stock had previously closed at $188.33. A number of research firms have recently []

These companies' struggles are temporary.

Related Stocks: BIIB , ANAB , CTMX , RIGL , BCAB , DRNA , VRTX , CYTK , URGN , XENE , PODD , MRTX , OCUL , XENT , KURA , VERV ,

Related Stocks: CXW , GEO , ATMR , MKTX , MA , CCV , LEGO , XLRN , UNP , AMZN , FB , PYPL , HLF , GLD , XEC , VRTX , UBER , IS ,

Related Stocks: PFE , TMO , TDOC , BMRN , JNJ , ALLO , VRTX , ATRA , ZNTL , TCRR , ACCD , JAZZ ,

Vertex Pharmaceuticals Incorporated is a leading biotech company that specializes in the treatment of genetic cystic fibrosis. Over the past five years, Vertex grew its revenue rapidly by a CAGR of 33

Related Stocks: CIBR , HD , TDG , GNRC , JSML , IXN , EMXC , MANH , ASML , HTGC , MELI , SPYG , KWEB , XTN , BLL , XSD , VRTX , IBM ,

Related Stocks: AMYT , TYME , GMDA , VRTX , DRRX , COLL , MDXG ,

LVM Capital Management Ltd. MI increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 31,525 shares of the pharmaceutical companys stock after purchasing an additional 645 shares during the period. LVM Capital []